Delivery Order SPE2DB20D1004-SPE2DB22FF8Y9
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp (a subsidiary of Cencora, Inc.) was issued by the Defense Logistics Agency (DLA) for the delivery of Nurtec ODT 75 mg tablets. The $21,819.43 firm fixed-price contract has a performance period through May 1, 2024 and does not include any set-aside requirements. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to...
- This contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Firm Fixed Price Delivery Order valued at $27,601.87. The award covers the delivery of Nurtec ODT 75 mg tablets to support the DLA's medical supply needs. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the...
- This federal contract award, valued at $9,425.31, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract provides for the delivery of Nurtec ODT 75 mg tablets, a pharmaceutical product, with a completion date of November 9, 2023. The contract is a Firm Fixed Price Delivery Order, without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp, as a major pharmaceutical distributor, holds a...
- This federal contract award, valued at $27,554.32, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of the pharmaceutical product Nurtec ODT 75 mg tablets, with a completion date of February 6, 2024. The contract is a firm-fixed-price delivery order, without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $2,368.55 Firm Fixed Price Delivery Order is for the supply of Nurtec ODT 75 mg tablets. The contract has an ultimate completion date of July 20, 2023 and was awarded on July 19, 2023. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was issued by the Defense Logistics Agency (DLA) on January 14, 2022. The $18,098.64 firm fixed-price delivery order is for the supply of Nurtec ODT 75 mg tablets. The contract has no set-aside designation, indicating open competition. Amerisourcebergen is a major pharmaceutical distributor that holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $14,574.44 for the pharmaceutical product Nurtec ODT 75 mg tablet. The award was issued by the Defense Logistics Agency (DLA), a defense agency responsible for providing logistics, acquisition, and technical services to the U.S. military. The contract does not have a set-aside designation, indicating it was awarded through full and open competition. Amerisourcebergen Drug...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $22,268.88 delivery order is for the pharmaceutical product Nurtec ODT 75 mg tablets. The contract is a firm-fixed-price delivery order with a completion date of January 13, 2022. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order (SPE2DB22D3004|SPE2DB24FPP52) valued at $34,627.60 for the pharmaceutical product Nurtec ODT 75 mg tablets. The award was made by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of March 7, 2024. The contract is a firm fixed-price delivery order with no set-aside designation, indicating open competition. Amerisourcebergen, a major pharmaceutical...
- This federal contract award, valued at $1,767.58, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Nurtec ODT 75 mg tablets and is a firm fixed-price delivery order. Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB22FF8Y9Delivery Order
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Nurtec ODT 75 mg tablets. The contract, valued at $1,054.76, was awarded by the Defense Logistics Agency (DLA) on July 11, 2022, with a completion date of July 12, 2022. The contract is a firm-fixed-price delivery order, with no set-aside designation. Amerisourcebergen, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, and other critical care materials, to support military healthcare programs globally. Additionally, Amerisourcebergen maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 7/11/22 |